Definitive Contract 140D6318C0114
Award Date
8/28/18
Potential Completion Date
3/27/20
Potential Value
$1.4M
Funding Federal Agency
Defense Advanced Research Projects Agency
Contracting Federal Agency
Interior Business Center
Awardee
Cytodel Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Set-Aside Type
Total Small Business
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10016, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee Delivery Order awarded by the Joint Program Executive Office for Chemical and Biological Defense, a component of the U.S. Department of the Army, to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.). The $107,935,344 award supports the clinical development of an FDA-licensed monoclonal antibody countermeasure for exposure to botulinum neurotoxin. The work will involve tasks such as clinical trials, process development, and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $73,836.80 contract is for the delivery of Botulinum Toxin Type A, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA...
This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...
This is a $3,026,999.00 firm fixed price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the development of a recombinant Type E botulinum neurotoxin vaccine. The contract has a completion date of September 29, 2006 and does not use a set-aside designation. Dynport Vaccine Company LLC is a limited liability company that provides research, development,...
This is a $225,000.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Technology Holding LLC, a small, for-profit limited liability company specializing in research and development services. The contract is part of DARPA's Small Business Innovation Research (SBIR) program and is for Phase I of an effort titled "AUTONOMOUS BIOMANUFACTORING AT REMOTE LOCATIONS". The contract has a total small business set-aside and supports the development of...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Xilis Inc., a for-profit manufacturing organization. The contract is for the development of tissue-derived droplet micro-organospheres as models for high-throughput testing of pathogens, with a total potential value of $224,658.00. The contract has a firm fixed price pricing type and a completion date of August 31, 2021. The original solicitation was a Broad...
This is a $3,247,731 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of a first-in-human therapeutic interfering particle targeting a respiratory virus, under DARPA's research programs. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) by DARPA, with a potential value of $4,579,822, to develop and deliver therapeutic...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $108,447.80 firm fixed-price delivery order is for the supply of Botulinum Toxin Type A, a pharmaceutical product, with a completion date of September 26, 2024. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the...
<p>This is a firm fixed-price SBIR Phase I contract awarded by the Joint PEO Chemical and Biological Defense, a Defense agency, to Cygnos Biotech, LLC, a small business located in Miami, Florida. The contract, valued at $204,493.42, is for research to create a class of agnostic drugs that can assist in fighting off a broad spectrum of viral pathogens. The contract has an ultimate completion date of August 9, 2025.</p>
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,306.64 award is for the delivery of 100-unit vials of the botulinum toxin product Botox. This contract is part of a larger indefinite delivery contract (IDC), valued at up to $499,999,999, that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This single-award IDC...